First Amendment to License Agreement with Clearside Biomedical, Inc., dated February 23, 2022

Exhibit 10.14

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

FIRST AMENDMENT TO LICENSE AGREEMENT

THIS FIRST AMENDMENT TO THE LICENSE AGREEMENT (the “First Amendment”) is

entered into as of February 23, 2022 (the “First Amendment Effective Date”) by and among

Aura Biosciences, Inc. (“AURA”) and Clearside Biomedical, Inc. (“COMPANY”), each

hereinafter referred to as a Party and both hereinafter referred to as“Parties”.

Recitals

WHEREAS, the Parties previously entered into that certain License Agreement effective July 3, 2019 (the “Agreement”);

Whereas, the Parties desire to enter into this First Amendment, to clarify and amend certain terms in the Agreement relating to the payment of developmental milestones thereunder, and set forth their mutual understandings with respect thereto.

Now, Therefore, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree that the Agreement shall be amended, effective as of the First Amendment Effective Date, as set forth below.

In Witness Whereof, the Parties have caused this First Amendment to be executed by

their respective duly authorized representatives as of the First Amendment Effective Date.